Sign Out
LOXOTOP PAP 100 mg Patch should be administered to women who are or are possibly pregnant only when the anticipated therapeutic benefits are considered to outweigh any potential risk. [The safety of LOXOTOP PAP 100 mg Patch in these populations has not been established.]
The following information is for reference only, the adverse reaction is not reported on the use of this product. It has been reported that constriction of the fetal ductus arteriosus is observed when woman in the late stage of pregnancy received other nonsteroidal anti-inflammatory-analgesic drugs for external use.
Renal impairment and decreased urine output in foetuses as well as accompanying oligohydramnios have been reported following use of cyclooxygenase inhibitors (oral dosage form or suppository) in pregnant women.
